Duda's group parazitii o chema focused on studies of tumor interaction with its microenvironment, with the goal of identifying the cellular and molecular mechanisms of: 1 local tumor progression in liver cancers and metastatic tumor progression in other gastrointestinal cancers and in prostate and breast malignanciesand 2 treatment resistance in advanced cancers.
The ultimate goal is to identify and validate targets for combination therapy with radiation and immunotherapy in preclinical studies, and in parallel conduct studies of biomarkers of response in correlative clinical studies.
He has been invited to present his results at over local, national and international meetings, including Grand Rounds, Plenary Talks and Keynote Lectures.
For his work, Dr. After graduation, he pursued postdoctoral training with Professor Rakesh K.
For more information, see full CV at: steele. Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma.
Clin Cancer Res A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat Clin Transl Radiat Oncol ; Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
Cancer Med Hepatology Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer PEACE : A study protocol.
Endosc Ultrasound JAMA Oncol Cancer Res ; FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
Neuroendocrine cancer with liver mets NPJ Breast Cancer ; Probing tumor neuroendocrine cancer with liver mets in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep ; Phase I and biomarker study of plerixafor and bevacizumab neuroendocrine cancer with liver mets recurrent high-grade glioma. Sci Transl Med Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Nat Rev Clin Oncol Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. NPJ Precis Oncol ; Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.
Theranostics ; Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.
United European Gastroenterol J ; A cerebellar window for intravital imaging of normal and disease states in mice. Nat Protoc ; Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage?
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Oncologist Feasibility, phase I, neuroendocrine cancer with liver mets phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Early changes in glioblastoma metabolism measured neuroendocrine cancer with liver mets MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol Am J Cancer Res ; Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.
Dan G. Duda
Oncolytic Virother ; Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway? Onco Targets Ther ; PubMed Duda DG. Keio J Med ; Cold Spring Harb Perspect Med Sci Transl Med ; ra EBioMedicine ; Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
- MATERIALS AND METHODS: Imaging studies of 22 patients 12 men, mean age 60 years with histopathologically confirmed diagnosis, evaluated in the authors's institution during the last five years were retrospectively reviewed by two radiologists, with findings being consensually described focusing on changes observed at computed tomography.
- Vaksinasi hpv adalah
- Dan G. Duda - DF/HCC
- Human papilloma virus strains
- Cancerul bucal simptome
A protein neuroendocrine cancer with liver mets mRNA expression-based classification of gastric cancer. Mod Pathol J Clin Oncol care sunt lojei paraziți în intestine Rationally combining anti-VEGF therapy with checkpoint inhibitors neuroendocrine cancer with liver mets hepatocellular carcinoma.
Journal of the National Cancer Institute Ecancermedicalscience ; Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Vascular diseases await translation of blood vessels engineered from stem cells. Sci Transl Med ; rv6.
Services on Demand
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma - an auto-commentary on clinical potential and future development.
Oncoimmunology ; 4:e Familial Gastric Cancers. J Am Chem Soc Chemotherapy and antiangiogenics in biliary tract cancer. Lancet Oncol.
Ileal neuroendocrine tumor – ultrasonographic and capsule endoscopy appearance: a case report
An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Reply to Ciccolini et al.
Keen realizează prima hepatectomie stângă în .
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
J Clin Oncol ; J Comput Assist Tomogr Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression.
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.
Med Hypotheses ; Seeds and soil: unraveling the role of local tumor stroma in distant metastasis. Characterization of functional transient receptor potential melastatin 8 channels in human pancreatic ductal adenocarcinoma cells.
Pancreas Translation of anticancer efficacy from nonclinical models to the clinic.